AKT1 and hepatocellular carcinoma: Conversely, the overexpression of the lncRNA activated in renal cell carcinoma with sunitinib resistance (lncARSR), which is markedly upregulated in HCC and is associated with disease progression, has been shown to activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by competing with phosphatase and tensin homolog (PTEN) mRNA, promoting doxorubicin resistance in HCC [76].